The FTSE 100 is down today, but Halma investors aren’t panicking

With the FTSE 100 down, Halma’s share price has barely budged today after it announced acquisitions. Is it worth buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life-saving technology group Halma (FTSE: HLMA) announced today that it had made another couple of acquisitions, NovaBone and FireMate. These will sit beside the other five companies bought by the group in its 2019 financial year. If you look back to at least 2014, there’s not one year in which it failed to make an acquisition.

The group increases its revenues and profits through a combination of acquisitions, partnerships and organic growth. Buying other companies is a fundamental part of its strategy, which has helped its share price go pretty much straight up for the last five years.

The shares’ longer-term performance is also encouraging. Shareholders enjoyed a total return of 1,141% from March 2009 to March 2019.

Fitting in

If the acquirer does its due diligence and doesn’t overpay for an acquisition that fits well with the company’s activities, then buying-in revenues and profits can add value for shareholders.

Of the two acquisitions announced today, one is a US-based designer and manufacturer of bone grafts, the other deals in cloud-based fire protection maintenance software for fire contractors.

Halma organises its businesses into four major segments: process, safety, infrastructure safety, environmental & analysis, and medical. The bone graft business fits nicely into the surgical applications subdivision of medical and the fire protection business slots into the fire subdivision of the infrastructure segment.

Looks like a bargain

NovaBone, the bone graft business, is being bought for approximately £74m in upfront cash, with up to £31m in add-ons depending on performance.

The group is paying about 14 to 20 times EBITDA for NovaBone (well below the 22.67 times average for the healthcare products industry). The price depends on performance and the new owner has forecast revenue and EBITDA of £16m and £5.3m respectively at its newly-acquired business. The price looks cheap to me.

Getting a 70% share of FireMate’s software business will cost Halma £6.2m upfront, with £3.3 in contingent payments. There’s an option to purchase the remaining shares exercisable in 2025.

Halma’s proportional share of FireMate’s last 12 months of EBIT would have been £0.35m and it’s paying 18 to 27 times EBIT for a controlling stake. Again, this multiple looks cheap compared to the 36 or 54 times EBIT averages paid for internet and system & application businesses.

The website Damodaran Online was used to find industry averages.

Not a bootstrapper

These are small acquisitions for Halma. Yet it’s encouraging to note that it doesn’t appear to be overpaying for businesses that fit well with existing operations.

Another issue with deal-hungry companies is that they sometimes buy growth to conceal weakness in their existing operations. According to Halma’s 2019 report, organic, constant currency growth ranged from 6.9% to 11.3% across its four divisions.

Organic, constant currency growth removes the distortions caused by acquisitions and exchange rate fluctuations. What it tells investors is that the group was growing well in 2019 before adding in acquired revenue. Since the pound weakened over the year, revenue growth on a non-constant-currency basis was even better.

At 2,161p, shares in Halma are not exactly cheap at 44 times consensus 2020 earnings of 49.6p. The forecast dividend yield is 0.8%, which is not awe-inspiring either. However, dividends and profits have grown by 7% and 13%, respectively, on average, over four years.

At the time of writing the FTSE 100 is down 2.4% but Halma’s share price has barely budged. For the long-term investor, the share looks like a good deal to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK has recommended Halma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »